BRÈVE

sur Defence Therapeutics Inc. (isin : CA24463V1013)

Defence Therapeutics' AccuTOX Study Published in Journal of Translational Medicine

Vancouver-based Defence Therapeutics Inc. has announced the publication of a peer-reviewed study on its anti-cancer molecule AccuTOX®. The study, "Local delivery of AccuTOX® synergises with immune-checkpoint inhibitors at disrupting tumor growth," appears in the Journal of Translational Medicine.

AccuTOX® is derived from the Accum® platform, initially designed to deliver biomedicines to target cells. AccuTOX® shows enhanced cancer cell killing ability, ease of manufacturing, and can serve as a cleavable anticancer molecule linked to antibodies.

The study highlights AccuTOX®'s superior therapeutic properties compared to its parent molecule Accum®. It induces cell death in various cancer cell lines, enhances immune system visibility of cancer cells, and works synergistically with immune-checkpoint inhibitors to control tumor growth.

Defence Therapeutics plans to expand clinical testing with an FDA-approved Phase I trial and recently submitted a CTA application to Health Canada.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Defence Therapeutics Inc.